undamentalytics Newsletter
Sign in

Bio-rad Laboratories, Inc. revenue

Bio-rad Laboratories, Inc.'s revenue was $2.58bn in fiscal 2025, up 0.7% on the year before. Since fiscal 2009 ($1.78bn) it has grown at a compound 2.3% a year. Over the last twelve months it was $2.59bn.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue1,7841,9272,0742,0692,1332,1752,0192,0682,1602,2892,3122,5462,9232,8022,6712,5672,5832,589
Growth on the year before—+8.0%+7.6%−0.2%+3.1%+2.0%−7.2%+2.4%+4.4%+6.0%+1.0%+10.1%+14.8%−4.1%−4.7%−3.9%+0.7%—
Gross profit1,0001,0911,1791,1551,1781,1791,1221,1381,1881,2231,2571,4381,6381,5671,4271,3791,3401,344
Gross margin56.0%56.6%56.9%55.8%55.3%54.2%55.5%55.0%55.0%53.4%54.4%56.5%56.1%55.9%53.4%53.7%51.9%51.9%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Clinical Diagnostics $1.6B 60.5% ▲ 1.6%
Life Science $1B 39.5% ▼ 0.7%
All Other Segments $0 0.0% ▼ 100.0%
Geography
Region Revenue Share YoY
United States $1B 39.6% ▼ 1.8%
Europe $882M 34.1% ▲ 5.7%
Asia Pacific $513M 19.9% ▼ 1.6%
Americas $165M 6.4% ▼ 2.3%

From Bio-rad Laboratories, Inc.'s 10-K filed February 13, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Life Sciences Tools & Services: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Bio-rad Laboratories, Inc. $2.59bn 1.4% -2.2%
Fortrea Holdings Inc. $2.67bn -3.4% 0.4%
Medpace Holdings, Inc. $2.84bn 20.4% 16.8%
Qiagen N.V. $2.09bn 5.7% 17.1%
Bruker Corp $3.50bn 1.6% 8.8%
Charles River Laboratories $4.00bn -0.7% -1.5%

Compare with peers

Head to head: BIO vs FTREBIO vs MEDPBIO vs QGEN

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Bio-rad Laboratories, Inc.'s SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bio-rad Laboratories, Inc.